WO2010081720A2 - Compositions for the treatment of gastro-esofageal reflux disease (gerd) - Google Patents
Compositions for the treatment of gastro-esofageal reflux disease (gerd) Download PDFInfo
- Publication number
- WO2010081720A2 WO2010081720A2 PCT/EP2010/000211 EP2010000211W WO2010081720A2 WO 2010081720 A2 WO2010081720 A2 WO 2010081720A2 EP 2010000211 W EP2010000211 W EP 2010000211W WO 2010081720 A2 WO2010081720 A2 WO 2010081720A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- gerd
- agents
- polysaccharides
- opuntia ficus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention provides oral pharmaceutical, nutraceutical, health foods and medical device compositions based on polysaccharides from
- Gastric esophagitis and related diseases including dyspepsia, esophagitis, esofageal tumour, gastro-intestinal symptoms, chronic pharyngitis, Barrett's esophagus, esophageal adenocarcinoma, GERD-related pulmonary symptoms, preferably in combination with different active substances for the same medical indications.
- compositions which proved to act synergistically, enables to use a lower effective dose of actives, improving their therapeutic index.
- Esophageal reflux occurs in physiological conditions, in particular in newborns, but when it overcomes the esofageal mucosa defence mechanisms, it may cause diseases such as GERD.
- GERD is the more frequent gastric disease and it is due to gastric or enteric reflux in the esophagus, leading to reflux esophagitis, a very common disease with typical esophageal mucosa inflammation and lesions (erosions and small ulcers) due to the gastric or enteric juice reflux in the esophagus.
- the anatomical structure mainly involved in maintaining the pressure gradient is the LES (Lower Esophageal Sphincter), a muscular ring at the esophagus and stomach joint, which relaxes during swallowing.
- LES Lower Esophageal Sphincter
- esophageal peristalsis esophageal muscle contractions
- GERD is characterized by similarity between pressures in the esophagus and in the stomach, respectively. This could be due to:
- the imperfect cardias closure may be due to different causes, such as obesity, smoke, multiple pregnancies, hard physical efforts, pharmacological treatments or hiatus hernia.
- Heartburn hard retrosternal burning
- burps and food or acid regurgitation in the mouth.
- These symptoms can be associated with others affecting the respiratory system (chronic cough, asthma, hoarseness, chronic laryngitis) teeth (enamel losing) or ear (otalgia).
- GERD and reflux esophagitis in case of acidic reflux, are currently treated with 1) proton pump inhibitors (PPI, e.g. omeprazole, lansoprazole) H 2 receptor antagonists (e.g. cimetidine and ranitidine), that reduce the acidic gastric secretion and consequently the reflux; 2) prokinetic agents (e.g. metoclopramide, domperidone, laevosulpiride), that increase the cardias valve tone and improve the gastric emptying; 3) antacid agents (e.g. bicarbonate, magnesium and aluminium hydroxide) and cytoprotective agents (e.g. sucralfate), that reduce gastric acidity and protect esophageal mucosa.
- PPI proton pump inhibitors
- H 2 receptor antagonists e.g. cimetidine and ranitidine
- prokinetic agents e.g. metoclopramide, domperidone, laevosulpiride
- Dietary, postural and behavioural rules that help to reduce or to prevent symptoms are associated with the pharmacological therapy. For example, it is recommended to avoid alcohol, abundant meals or fatty, spicy or irritant foods
- the pharmacological therapy does not affect the disease's cause (ill- functioning cardias) and it must be taken for very long periods (even the entire life) as almost all patients suffer from disease recurrence once the therapy is interrupted.
- the dysfunctional cardias valve closure may be corrected with surgical therapy: this leads to perfect recovery from the disease, but if it is not well performed it may determine the appearance of new symptoms. Moreover, the surgical treatment is recommended for young subjects, in excellent general condition and who are in need of continuous high dose therapy. Recently Dr. Higa proposed a new surgical method able to reduce GERD, but this new technique is not very widespread (http://www.medwatchtoday.eom/l 1 13.htm). There are not clear indications for preferring one specific pharmacological therapy for the treatment of GERD or reflux esophagitis: physicians choose in general on the basis of their personal experience. Consequently, the choice of the therapy is very personal and not objective and it is possible that a physician has to try more than one pharmacological therapy prior to find the therapy best fitting the patient's physiology.
- H 2 antagonists anti H 2
- PPI proton pump inhibitors
- PPIs are much effective actives, but their prolonged use (which is needed in reflux esophagitis therapy) revealed serious side effects related to the long-term therapy with this class of actives such as increased risk of hip fracture as a result of calcium erratic absorption due to induction of hypochlorhidya (Yang et al., Long term proton pomp inhibitor therapy and risk of hip fracture, JAMA 2006, 296(94): 2947-2953), muscle diseases as well as polymyositis and rabdomiolisis (Clark et al., Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? , Eur. J.
- Salquiero et al. (Salquiero et al., Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions, Int. J.
- Alginates which have a physical mechanism of action (gelling and foaming at the acidic gastric pH, in presence of HCO 3 " ) are safer than PPIs, but are not useful in the treatment of non-acid esophageal reflux (Zentlin et al., An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry, Aliment Pharmacol Ther. 2005; 21: 29-34).
- diseases such as
- GERD reflux esophagitis and related diseases (dyspepsia, esophagitis, esophageal tumour, gastrointestinal disorders, chronic pharyngitis, Barrett's esophagus, esofageal adenocarcinoma, GERD-related pulmonary dysfunctions) are increasing, it is highly desirable to find a safe and effective treatment for the prevention and therapy of such diseases, avoiding the patient to undergo different treatments at the same time to obtain an effective therapeutic result.
- the invention provides pharmaceutical, nutraceutical, health foods and medical device compositions able to co-operate in a synergistic way with active substances useful in the prevention and therapy of acid and non-acid esophageal reflux diseases and their clinical complications.
- These compositions are characterized by containing a polysaccharide extract from Opuntia Ficus Indica cladodes.
- Opuntia Ficus Indica (Nopal) is a plant belonging to Cactaceae, native to Mexico and to United States south-west, but widespread even in self-sown Mediterranean vegetation.
- cladodes are used from ancient times for dietary use (the cladodes are used fresh, brined, pickled, candied, as jam and even as forage) or to prepare alcoholic drinks.
- Opuntia Ficus Indica fruits have marked antioxidant properties (Tesoriere et al., Supplementation with cactus pear (Opuntia fxcus-in ⁇ icsi) fruit decreases oxidative stress in healthy humans: a comparative study with vitamin C, Am J Clin Nutr. 2004 Aug; 80(2): 391-395); 2) an Opuntia Ficus Indica extract is effective in the alcohol hangover therapy (Wiese J et al., Effect of Opuntia Ficus Indica on symptoms of the alcohol hangover, Arch Intern Med.
- Opuntia cladodes essentially formed by a polymer of galactose, arabinose and other sugars, has the property of linking swallowed fat and sugars (so preventing their absorption) thereby improving glyco-lipidic metabolisms and metabolic syndrome;
- Opuntia Ficus Indica cladodes mucilages and pectins proved to be gastro protective in experimental animal models (Vazquez-Ramirez R.
- Opuntia Ficus Indica cladodes exert synergistic activities with substances useful for the prevention and treatment of GERD and its complications.
- the invention provides pharmaceutical, nutraceutical, health foods and medical device formulations suitable for oral administration, comprising polysaccharides extracted from Opuntia Ficus Indica cladodes, preferably in combination with active substances used for the prevention and therapy of diseases of the upper gastrointestinal tract and particularly GERD, reflux esophagitis and related diseases (dyspepsia, esophagitis, esophageal tumour, gastrointestinal disturbs, chronic pharyngitis, Barrett's esophagus, esophageal adenocarcinoma, pulmonary dysfunctions GERD related).
- the active substances used in combination with the polysaccharides extracted from Opuntia Ficus Indica cladodes include, but are not limited to, antacid agents, proton pump inhibitors, H 2 antagonists, prokinetic agents, sodium bicarbonate, alginic acid or alginates, chitosanes, aluminum hydroxide, calcium or magnesium carbonate, antioxidant and anti-inflammatory flavonoides extracted from plants as well as from olive leaves or Capparis Spinosa buttons, anthocianosides from red oranges, black rice or from other natural sources, and their combinations.
- compositions allow to reduce the dose of pharmacologically active substances and possess high therapeutic safety, which is particularly important in children, pregnant women and elderly people, or in those cases where long therapy with NAIDS (Non Steroidal Anti Inflammatory Drugs) is co-administered.
- NAIDS Non Steroidal Anti Inflammatory Drugs
- gastrointestinal tract diseases such as dyspepsia, esophagitis, esophageal tumour, Barrett's esophagus, esophageal adenocarcinoma, GERD-related pulmonary dysfunctions, also in combination with other therapies for the same diseases.
- a first aspect of the invention is therefore the provision of pharmaceutical, nutraceutical, health foods and medical .
- device oral compositions comprising polysaccharides from Opuntia Ficus Indica cladodes preferably in combination with active substances useful to prevent or cure upper gastrointestinal tract diseases, as defined in the attached claims.
- the term "combination” indicates either a physical or a functional association of extracts and active substances.
- the active ingredients are formulated in the same composition with carriers, excipients or other ingredients suitable for the purpose of use.
- the active ingredients can be administered in separate compositions or through separate routes, in order to reach a combined therapeutic effect.
- a second aspect of the invention is the use of said compositions for the preparation of a medicament to treat GERD, dyspepsia, esophagitis, esophageal tumour, gastrointestinal disturbs, chronic pharyngitis, Barrett's esophagus, esophageal adenocarcinoma, pulmonary dysphunctions GERD related, in combination with active substances known to prevent and cure the same diseases, whose efficacy is increased by the synergistic activity of Opuntia Ficus Indica cladodes polysaccharides, such active substances being preferably selected from antacid agents, proton pump inhibitors, H2 antagonists, prokinetic agents, sodium bicarbonate, alginic acid or alginates, chitosanes, aluminium or magnesium hydroxide, calcium or magnesium carbonate, antioxidant and anti- inflammatory flavonoides extracted from plants as well as from olive leaves or Capparis Spinosa buttons, anthocianosides from red oranges,
- Opuntia Ficus Indica cladodes polysaccharides - which are optionally supported by maltodextrins (up to 50%) - can be provided in the form of mucilages, which can be isolated through cladode squeezing or by treatment with water at ambient temperature.
- the cladodes are pressed, the thus obtained juice is centrifuged and the liquid supernatant is subjected to ultrafiltration, thereby obtaining an aqueous solution enriched in polysaccharides (Molecular Weight higher than 10 4 Da). Subsequently the aqueous solution can be concentrated and dried.
- the polysaccharide content in the Opuntia f ⁇ cus indica cladode extract generally ranges from 1 to 70% by weight.
- the chemical structure and composition of Opuntia ficus indica cladode polysaccharide has been studied and characterized (D. McGarvie, H. Parous, Methylation analysis of the mucilage of Opuntia ficus indie. Carbohydrate Research, (1981) 88: 305-314; M. S. Karawya et al. Mucilages and Pectines of Opuntia, Tamarindus and Cydonia. Planta Medica (1980) Supplement:68-75; M. E. Malainine et al. Structure and morphology of cladodes and spines of Opuntia ficus indica. Cellulose extraction and characterisation. Carbohydrate polymers (2003) 51 :77-83).
- the mucilages are made of residues of 1,4- ⁇ -D-galactopyranosyl-uronic acid and 1,2- ⁇ -L-rhamnopyranosides which are attached to short 1,6- ⁇ -D-galactopyranose chains in position 4 of all rhamnopyranose residues.
- Most of galctoside residues bear chains in O-3 or O-4 which mainly consist of arabinofuranoside, arabinofuranoside-xylopyranoside residues (D. McGarvie, H. Parous, Methylation analysis of the mucilage of Opuntia ficus indie. Carbohydrate Research, (1981) 88: 305-314).
- the mucilages contained in Opuntia ficus indica cladodes are generally isolated through a squeezing process (D. Trombetta et al. Effect of polysaccharides from Opuntia ficus-indica (L.) cladodes on the healing of dermal wounds in the rat. Phytomedicine (2006) 13: 352-358) or by water treatment (R. Vazquez-Ramirez et al. Reversing gastric mucosal alterations during ethanol- induced chronic gastritis in rats by oral administration of Opuntia ficus-indica mucilage. World J Gastroenterol (2006) 12(27):4318-4324) :
- compositions of the invention can be liquid or solid, suitable for oral administration, preferably in the form of oral solutions, oral suspensions, oral emulsions, tablets, powders and tablets for extemporaneous preparation.
- the term “medical device” means an "Active medical device” (class I) in accordance with the Directive 93/42/EEC Annex IX classification.
- the compositions of the invention may include preservatives, ionic and non ionic buffered agents and additives commonly used in the preparation of oral compositions.
- the solvent is preferably water or a multiple-component aqueous solution compatible with the oral use.
- the active substances useful for treating or preventing upper gastrointestinal tract diseases to be used in combination with the Opuntia Ficus Indica cladodes extract of the invention include: 1) substances yet used for the cure of the same diseases such as proton pump inhibitors, H2 antagonists, prokinetic agents, antacid agents, sodium bicarbonate, alginic acid or alginates, chitosanes, sodium bicarbonate and their combinations; 2) natural substances such as antioxidant and anti inflammatory flavonoides from plants, e.g. from Capparis Spinosa buttons, antocyanosides from red oranges, black rice or other natural sources and preferably extracts of olive leaves; 3) combinations between 1) and 2).
- Olea europeae leaves can be extracted with aqueous or hydroalcoholic solvents (10-80% ethanol) at ambient temperature or heating up to 60-70 0 C, or by treatment with microwaves, ultrasounds or by superheated liquid extraction (Lee O. H. et al. Assessment of phenolics-enriched extract and fractions of olive leaves and their antioxidant activities Bioresour Technol (2009) Epub ahead of print; Mylonaki S. et al. Optimisation of the extraction of olive (olea europaea) leaf phenplics using water ⁇ ethanol-based solvent systems and response surface methodology. Anal Bioanal Chem. (2008) 392(5):977-85 ; Jap ⁇ n-Lujan R, Luque de Castro MD.
- the aqueous or hydroalcoholic solvent is removed under vacuum at 40 0 C. Further enrichment in biophenols can be obtained by loading the dried extract onto styrene resins and eluting with 50:50 ethanol/water solution.
- the Olea europeae leaves extract contains phenols (tyrosol, hydroxytyrosol and derivatives thereof), cinnamic acids, flavonoids (apigenin, luteolin and glucoside derivatives thereof, rutin, quercetin), lignans, secoiridoids (oleuroside, oleuropeine and derivatives thereof, elenolic acid) and specifically contains the following polyphenolic profile: 2-40% flavonoids (apigenin, luteolin and derivatives thereof), 0.5-10% oleuropeine, 1-30% hydroxytyrosol and derivatives thereof.
- Methods for preparing pharmaceutical or nutraceutical compositions are known in the art.
- the content of Opuntia Ficus Indica extracted polysaccharides preferably ranges from 0.5 to 50% w/w of the total compositions; the other actives may be in amounts from 1 to 30%.
- Opuntia ficus indica polysaccharides which are currently used in dietaries, are suitable and safe for particular patients categories such as elderly people, children or pregnant women.
- the present invention further provides the use of the compositions for treating and preventing upper gastrointestinal tract diseases by administration of therapeutically effective amounts of Opuntia polysaccharides to a subject in need thereof, preferably in combination with active substances useful for treating or preventing the same diseases.
- compositions of the present invention include: gastroesophageal reflux,
- GERD dyspepsia, esophagitis, and esophageal tumour
- gastrointestinal disturbs chronic pharyngitis
- Barrett's esophagus esophageal adenocarcinoma
- GERD-related pulmonary dysfunctions GERD-related pulmonary dysfunctions.
- Figure IA photograph of cladodes and fruits of Opuntia Ficus Indica; - Figure 2: in vitro model of mucoadhesion;
- Figure 3 comparison of the synergistic effect of polysaccharides extracted from Opuntia Ficus Indica cladodes with sodium alginate with respect to the individual components in an in vitro model on epithelial buccal mucosa cells; - Figure 4: mucoadhesion (inhibition percentage of lectin binding after treatment) for each tested substances compared in Fig. 3.
- Figure 5 gastric anti-ulcerogenic effect of different substances or susbtances combination tested in different experimental models of chemical gastric ulcer in rats. Data are reported as mean ⁇ SD of 6 animals; in parenthesis the percent inhibition compared to the control group.
- Figure 6 esophageal anti-ulcerogenic effect of different substances or substances combination tested in a model of gastroesophageal reflux surgically induced. Data are reported as mean ⁇ SD of 6 animals; in parenthesis the percent inhibition compared to the control group.
- compositions according to the invention are reported in the following tables.
- Patel (Patel D. and al., An in vitro mucosal model predictive of bioadhesive agents in the oral cavity. J Control Release, 1999, 61(1-2): 175-183) was applied to suspended epithelial cells from buccal mucosa. In this test, mucoadhesion
- adheresive capability of the tested substances to the mucosal cells is determined as a function of lectin-membrane glycoprotein binding inhibition induced by the cellular surface-masking due to the mucoadhesive substance.
- Lectin is a protein contained in some plants of Leguminosae ⁇ Canavalia ensiformis), with high tendency to bind glucosidic and mannosidic residues of membrane glycoproteins; biotin (vitamin H) is bonded to lectin through streptavidin peroxidase that is added to cellular suspension to obtain the complex protein-glucose-lectin-biotin-streptavidin peroxidase.
- o-pd o-phenylendiamine dihydrochloride
- hydrogen peroxide By addition of o-phenylendiamine dihydrochloride (o-pd) and hydrogen peroxide to the cellular suspension, o-pd is oxidized by the complex protein- glucose-lectin-biotin-streptavidin peroxidase to 2,3-diaminophenazine, and the sample becomes yellow (Fig. 2).
- each sample contained 48 x 10 4 buccal mucosa cells.
- Polysaccharides from Opuntia Ficus Indica cladodes and sodium alginate were solubilised in NaCl 0.9% isotonic solution at 0.5% w ⁇ v and these solutions were then used for the pre-treatment of buccal mucosa cells. Results are expressed as percentage of tested substance and mucosa cells binding, which is inversely proportional to percent reduction of sample colouring compared to the control.
- the assay shows a 55.81% Opuntia Ficus Indica polysaccharides mucoadhesion to buccal mucosa suspended cells, significantly higher than that observed with sodium alginate (mucoadhesion
- Opuntia ficus Indica cladodes polysaccharides, mucoadhesion reaches 74.83%.
- Opuntia Ficus Indica cladodes polysaccharides exhibit higher mucoadhesion than that observed with sodium alginate. It was moreover unexpectedly found that the combination of these substances determines a synergistic effect that guarantees a strengthened mucoadhesive activity.
- Each sample was obtained by water suspension (concentrations reported in Table 7) and administered with an oral pump (1 ml lOOg weight).
- the experiment was performed on male Wistar (Rattus norvegicus) adult rats, weighing from 180 to 200 g.
- the animals were exposed to natural light (12:12 h light and night cycles) in controlled temperature (24 ⁇ I 0 C) and humidity (60% ⁇ 4) conditions, and supplied standard food (Morini Mill rat GLP) and water ad libitum for one week.
- the animals were then deprived of food 24 hours, and of water 2 hours before the start of the experiment (F. Vitali, Antiulcer potential of a standardized extract of red orange juice in the rat, Int J Food Properties, 10, 331-344, 2007).
- Group 1 was used as control and was treated with the vehicle (sample F, Carbopol 919 0.3% w/v and calcium carbonate 1% w/v in distilled water neutralized with NaOH, 1 ml/ 100 g weight) and, after 1 hour, with the ulcerogenic agent: absolute ethanol 1 ml/rat; groups 2-6 were orally administered samples A (767 mg /kg weight, Group 2), B (200 mg /kg weight - Group 3), C (100 mg /kg weight - Group 4), D (967 mg /kg weight - Group 5) and E (1067 mg /kg weight - Group 6). After 1 hour from administration of samples A-E, the animals of groups 2-6 received 1 ml/animal of absolute ethanol, to induce the ulcer.
- the vehicle sample F, Carbopol 919 0.3% w/v and calcium carbonate 1% w/v in distilled water neutralized with NaOH, 1 ml/ 100 g weight
- the ulcerogenic agent absolute ethanol 1 ml/rat
- the animals of Group 1 were orally administered the vehicle (sample F, Carbopol 919 0.3% w/v and calcium carbonate 1% w/v in distilled water neutralized with NaOH, 1 ml/100 g weight) and, after 1 hour, the ulgerpgenic agent Indomethacin (suspension in distilled water containing carboxymethylcellulose 1%) at 0.03 g/Kg dose, (1 ml/Kg weight) s.c.
- Groups 2-6 were treated as described above for ethanol-induced ulcer, with samples A-E and, after 1 hour, with Indomethacin suspension. After 5 hours from the treatment with Indomethacin, the animals were anesthetised with diethyl ether and sacrificed. The stomach of each animal was then removed, and analysed as described in the experiment with ethanol.
- the ulcer lesions observed in animals receiving conventional treatments scored very high compared to the animals treated with the combination of the invention, demonstrating a synergistic effect of its individual components.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2749751A CA2749751C (en) | 2009-01-16 | 2010-01-15 | Compositions for the treatment of gastro-esophageal reflux disease (gerd) |
US13/144,413 US9610315B2 (en) | 2009-01-16 | 2010-01-15 | Compositions for the treatment of gastro-esophageal reflux disease (GERD) |
BRPI1006821A BRPI1006821A2 (en) | 2009-01-16 | 2010-01-15 | compositions for the treatment of gastroesophageal reflux disease (gerd). |
EP10702412.7A EP2379093B1 (en) | 2009-01-16 | 2010-01-15 | Compositions for the treatment of gastroesophageal reflux disease (gerd) |
ES10702412.7T ES2613308T3 (en) | 2009-01-16 | 2010-01-15 | Compositions for the treatment of gastroesophageal reflux disease (GERD) |
CN201080004663.0A CN102281887B (en) | 2009-01-16 | 2010-01-15 | Compositions for the treatment of gastro-esofageal reflux disease (GERD) |
RU2011129304/15A RU2524639C2 (en) | 2009-01-16 | 2010-01-15 | Compositions for treatment of gastroesophageal reflux disease (gerd) |
HK12105049.6A HK1164149A1 (en) | 2009-01-16 | 2012-05-23 | Compositions for the treatment of gastro-esofageal reflux disease (gerd) -(gerd) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09425009.9 | 2009-01-16 | ||
EP09425009A EP2208500A1 (en) | 2009-01-16 | 2009-01-16 | Compositions for the treatment of gerd (gastroesophageal reflux disease) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010081720A2 true WO2010081720A2 (en) | 2010-07-22 |
WO2010081720A3 WO2010081720A3 (en) | 2010-09-23 |
Family
ID=41139004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/000211 WO2010081720A2 (en) | 2009-01-16 | 2010-01-15 | Compositions for the treatment of gastro-esofageal reflux disease (gerd) |
Country Status (10)
Country | Link |
---|---|
US (1) | US9610315B2 (en) |
EP (2) | EP2208500A1 (en) |
CN (1) | CN102281887B (en) |
BR (1) | BRPI1006821A2 (en) |
CA (1) | CA2749751C (en) |
ES (1) | ES2613308T3 (en) |
HK (1) | HK1164149A1 (en) |
PL (1) | PL2379093T3 (en) |
RU (1) | RU2524639C2 (en) |
WO (1) | WO2010081720A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013121452A1 (en) | 2012-02-08 | 2013-08-22 | Dicofarm S.P.A. | Product comprising glucomannan and chitosan for the treatment gastroesophageal reflux disease |
WO2023139414A1 (en) * | 2022-01-24 | 2023-07-27 | Metis Healthcare S.R.L. | Composition for treating esophageal reflux |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20120084A1 (en) * | 2012-03-07 | 2013-09-08 | Aboca Spa Societa Agricola | PREBIOTIC MIXTURE. |
KR101417287B1 (en) * | 2012-06-15 | 2014-07-08 | 동아제약 주식회사 | Novel composition for the treatment of gastroesophageal reflux disease |
RU2501549C1 (en) | 2012-08-30 | 2013-12-20 | Авва Девелопмент Лтд | Pharmaceutical composition for treating gastroesophageal reflux disease |
KR101396458B1 (en) | 2013-08-09 | 2014-05-20 | 양미란 | A food or drink composition comprising fermented eastern prickly pear |
KR102303835B1 (en) * | 2014-01-08 | 2021-09-16 | 영진약품 주식회사 | Aqueous flowable liquid composition and preparing methode thereof |
MX356127B (en) * | 2014-02-18 | 2018-04-24 | Univ Mexico Nac Autonoma | Nopal mucilage (opuntia ficus-indica) as a controlled-release vehicle and adjuvant for regeneration of the mucosa of the gastrointestinal tract. |
EP3157540A1 (en) * | 2014-05-15 | 2017-04-26 | Pesle, Livio | Decoction of olive leaves |
CN104127667B (en) * | 2014-07-13 | 2017-09-01 | 梁军 | It is a kind of to treat pharmaceutical composition of chronic pharyngitis and preparation method thereof |
CN106860852A (en) * | 2017-02-17 | 2017-06-20 | 王清华 | A kind of mucus Western medicine for combined treatment stomach trouble |
CN106924738B (en) * | 2017-03-06 | 2019-12-03 | 北京大学第三医院 | The pharmaceutical composition for preventing lemostenosis |
IT201700090582A1 (en) * | 2017-08-04 | 2019-02-04 | Neilos S R L | Composition for use in the prevention and / or treatment of gastric or gastroesophageal disorders. |
IT201700108526A1 (en) * | 2017-09-28 | 2019-03-28 | Alfasigma Spa | ORAL COMPOSITIONS FOR THE TREATMENT OF GASTROESOPHAGEAL REFLECTION. |
IT201700124434A1 (en) * | 2017-10-31 | 2019-05-01 | Sofar Swiss Sa | Tablet to suck and / or dissolve in the mouth based on hyaluronic acid and chondroitin sulfate and their salts for use in the treatment of a subpopulation of GERD patients. |
CN109432232B (en) * | 2018-12-07 | 2021-11-26 | 纽湃腾(北京)医药科技有限公司 | Alginate composition for improving and regulating gastroesophageal reflux and application thereof |
IT201900024958A1 (en) * | 2019-12-20 | 2021-06-20 | Neilos S R L | Composition for the protection of the gastrointestinal mucosa and for the prevention and treatment of associated pathologies |
EP4240372A1 (en) * | 2020-11-03 | 2023-09-13 | Neilos S.r.l. | Composition for use in the prevention and treatment of diseases of the gastrointestinal system and of the related symptoms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10027050A1 (en) * | 2000-06-02 | 2001-12-13 | Karim Balan | Therapeutic composition containing alginate preparation and plant extract, useful e.g. for immunomodulation or treatment of gastrointestinal disorders, migraine, rheumatism or diabetes |
US6447820B1 (en) * | 2001-01-22 | 2002-09-10 | Sarfaraz K Niazi | Pharmaceutical composition for the prevention and treatment of scar tissue |
EP1596821A2 (en) * | 2003-01-24 | 2005-11-23 | The State Of Israel-Ministry Of Agriculture | Synergistic compositions and methods for potentiating anti-oxidative activity |
US7429396B2 (en) * | 2003-02-25 | 2008-09-30 | Bio-Botanica, Inc. | Antifungal composition, its fungicidal effect on pathogenic dermatophytes, and process for inhibiting growth of fungi |
US20070203242A1 (en) * | 2006-02-27 | 2007-08-30 | Calwood Nutritionals, Inc. | Method for treating gastric reflux |
EP2057994A1 (en) | 2007-11-06 | 2009-05-13 | Finzelberg GmbH & Co. KG | Prickly pear extract preparation |
-
2009
- 2009-01-16 EP EP09425009A patent/EP2208500A1/en not_active Withdrawn
-
2010
- 2010-01-15 EP EP10702412.7A patent/EP2379093B1/en active Active
- 2010-01-15 BR BRPI1006821A patent/BRPI1006821A2/en not_active Application Discontinuation
- 2010-01-15 WO PCT/EP2010/000211 patent/WO2010081720A2/en active Application Filing
- 2010-01-15 RU RU2011129304/15A patent/RU2524639C2/en not_active IP Right Cessation
- 2010-01-15 ES ES10702412.7T patent/ES2613308T3/en active Active
- 2010-01-15 US US13/144,413 patent/US9610315B2/en active Active
- 2010-01-15 CN CN201080004663.0A patent/CN102281887B/en not_active Expired - Fee Related
- 2010-01-15 PL PL10702412T patent/PL2379093T3/en unknown
- 2010-01-15 CA CA2749751A patent/CA2749751C/en not_active Expired - Fee Related
-
2012
- 2012-05-23 HK HK12105049.6A patent/HK1164149A1/en not_active IP Right Cessation
Non-Patent Citations (24)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013121452A1 (en) | 2012-02-08 | 2013-08-22 | Dicofarm S.P.A. | Product comprising glucomannan and chitosan for the treatment gastroesophageal reflux disease |
WO2023139414A1 (en) * | 2022-01-24 | 2023-07-27 | Metis Healthcare S.R.L. | Composition for treating esophageal reflux |
Also Published As
Publication number | Publication date |
---|---|
CA2749751C (en) | 2019-09-17 |
EP2208500A1 (en) | 2010-07-21 |
EP2379093B1 (en) | 2016-11-23 |
CN102281887B (en) | 2014-10-29 |
CA2749751A1 (en) | 2010-07-22 |
RU2011129304A (en) | 2013-02-27 |
EP2379093A2 (en) | 2011-10-26 |
US20110318432A1 (en) | 2011-12-29 |
CN102281887A (en) | 2011-12-14 |
HK1164149A1 (en) | 2012-09-21 |
WO2010081720A3 (en) | 2010-09-23 |
US9610315B2 (en) | 2017-04-04 |
PL2379093T3 (en) | 2017-05-31 |
RU2524639C2 (en) | 2014-07-27 |
BRPI1006821A2 (en) | 2016-09-13 |
ES2613308T3 (en) | 2017-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9610315B2 (en) | Compositions for the treatment of gastro-esophageal reflux disease (GERD) | |
KR20090127523A (en) | Composition for treating atopy and acne | |
US20050287235A1 (en) | Antiulcer herbal compositions | |
EP3124048B1 (en) | Composition for oral use in the treatment of gastro-oesophageal reflux disease or discomfort | |
EP4106771A1 (en) | Composition for the protection of the gastrointestinal mucosa and for the prevention and treatment of diseases associated therewith | |
Prajapati et al. | Overview on antiulcer activity of Basella alba: a therapeutic herb | |
WO2021124306A1 (en) | Composition for the protection of the gastrointestinal mucosa and for the prevention and treatment of diseases associated therewith | |
WO2021144727A1 (en) | Composition for the protection of gastric mucosa | |
Srivastava et al. | Evaluation of anti-ulcer activity of methanolic extract of Lagenaria siceraria | |
Berzofsky et al. | The treatment of reflux disease: standard and alternative approach | |
EP3661533A1 (en) | A composition for use in the prevention and/or treatment of gastric or gastroesophageal diseases | |
KR102412392B1 (en) | Cheongwitang Composition | |
US11723939B2 (en) | Composition for gastric and oesophageal diseases | |
EP4240372A1 (en) | Composition for use in the prevention and treatment of diseases of the gastrointestinal system and of the related symptoms | |
IT202100021995A1 (en) | Composition for the prevention and/or treatment of gastric and oesophageal pathologies | |
Mitra et al. | Hyperacidity (Amlapitta) | |
IT202100021992A1 (en) | Composition for the prevention and/or treatment of gastric and oesophageal pathologies | |
WO2019030629A1 (en) | A composition for oral administration in the therapeutic or preventive treatment of gastroesophageal reflux disorders or disease | |
US10076550B2 (en) | Synergistic pharmaceutical composition for gastroinestinal disorders | |
Halpern | 11 Peptic Ulcer Disease and Helicobacter pylori | |
KR20200127730A (en) | Composition comprising extracts of Houttuynia cordata for acute gastritis and gastric mucosal protection | |
Olivier | Specific botanicals as an aid for acid reflux | |
Singh et al. | Herbal Remedies Used for the Treatment of Peptic Ulcer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080004663.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10702412 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
REEP | Request for entry into the european phase |
Ref document number: 2010702412 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010702412 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2749751 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011129304 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13144413 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1006821 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1006821 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110714 |